ZIVO
ZIVO Bioscience, Inc.
Price Chart
Latest Quote
$3.72
+0.00 (+0.00%)
Current Price
| Previous Close | $3.72 |
| Open | $3.06 |
| Day High | $3.06 |
| Day Low | $3.06 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 4.15M |
| Total Debt | $820K |
| Cash Equivalents | $57K |
| Revenue | $209K |
| Net Income | $-8.49M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $15.44M |
| EPS (TTM) | $-2.18 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.62M |
| Sales | $209K |
| Income | $-8.49M |
| Book/sh | $-0.86 |
| Cash/sh | $0.01 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 0.02 |
| Current Ratio | 0.08 |
Returns & Margins
| ROA | -1001.91% |
| Gross Margin | 31.67% |
| Operating Margin | -1551.76% |
Ownership
| Insider Ownership | 47.46% |
| Institutional Ownership | 0.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.10 |
| P/S | 73.89 |
| P/B | -4.34 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.94 |
| SMA50 | $3.71 |
| SMA200 | $9.48 |
| RSI | 50.75 |
| ATR | 0.2243 |
| Shares Float | 1.38M |
| Short Float | 2.61% |
| Short Ratio | 6.65 |
| Volatility | 0.09 |
Performance History
| Week | -15.45% |
| Month | -12.47% |
| Quarter | -59.78% |
| 6 Months | -64.06% |
| YTD | -62.50% |
| Year | -78.75% |
| 3 Years | -78.09% |
| 5 Years | -93.54% |
| 10 Years | -84.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $3.72 | 0 |
| 2026-06-03 | $3.72 | 2,000 |
| 2026-06-02 | $4.40 | 0 |
| 2026-06-01 | $4.40 | 0 |
| 2026-05-29 | $4.40 | 1,200 |
| 2026-05-28 | $4.40 | 500 |
| 2026-05-27 | $4.60 | 100 |
| 2026-05-26 | $4.00 | 1,000 |
| 2026-05-22 | $4.10 | 500 |
| 2026-05-21 | $4.06 | 0 |
| 2026-05-20 | $4.06 | 0 |
| 2026-05-19 | $4.06 | 0 |
| 2026-05-18 | $4.06 | 300 |
| 2026-05-15 | $3.69 | 0 |
| 2026-05-14 | $3.69 | 7,000 |
| 2026-05-13 | $2.70 | 1,500 |
| 2026-05-12 | $3.25 | 3,800 |
| 2026-05-11 | $3.75 | 0 |
| 2026-05-08 | $3.75 | 4,500 |
| 2026-05-07 | $4.00 | 4,800 |
| 2026-05-06 | $4.00 | 400 |
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
đ° Latest News
No news articles available at the moment. Check back later for updates on ZIVO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $108,268 | $16,040 | $0 | - |
| Cost Of Revenue | $108,268 | $16,040 | $0 | - |
| Total Revenue | $157,220 | $27,650 | $0 | $0 |
| Operating Revenue | $157,220 | $27,650 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $22,939 | $514,172 | $13,319 | $233,282 |
| Total Expenses | $13,519,117 | $7,290,662 | $8,731,974 | $8,645,119 |
| Net Non Operating Interest Income Expense | $-22,939 | $-514,172 | $-13,319 | $-233,282 |
| Interest Expense Non Operating | $22,939 | $514,172 | $13,319 | $233,282 |
| Operating Expense | $13,410,849 | $7,274,622 | $8,731,974 | $8,645,119 |
| General And Administrative Expense | $10,275,914 | $5,897,594 | $6,491,704 | $6,694,619 |
| Other Income Expense | - | - | - | $122,520 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Net Interest Income | $-22,939 | $-514,172 | $-13,319 | $-233,282 |
| Normalized Income | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,878,401 |
| Net Income From Continuing And Discontinued Operation | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Total Operating Income As Reported | $-13,361,897 | $-7,263,012 | $-8,731,974 | $-8,645,119 |
| Net Income Common Stockholders | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Net Income | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Net Income Including Noncontrolling Interests | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Net Income Continuous Operations | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Pretax Income | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Operating Income | $-13,361,897 | $-7,263,012 | $-8,731,974 | $-8,645,119 |
| Gross Profit | $48,952 | $11,610 | $0 | - |
| Special Income Charges | - | - | $0 | $122,520 |
| Per Share | ||||
| Diluted EPS | $-4.23 | $-4.60 | $-5.57 | $-6.90 |
| Basic EPS | $-4.23 | $-4.60 | $-5.57 | $-6.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,361,897 | $-7,263,012 | $-8,731,974 | $-8,645,119 |
| EBITDA (Bullshit earnings) | $-13,361,897 | $-7,263,012 | $-8,731,974 | $-8,522,599 |
| EBIT | $-13,361,897 | $-7,263,012 | $-8,731,974 | $-8,522,599 |
| Diluted Average Shares | $3,167,153 | $1,690,009 | $1,569,943 | $1,271,511 |
| Basic Average Shares | $3,167,153 | $1,690,009 | $1,569,943 | $1,271,511 |
| Diluted NI Availto Com Stockholders | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Research And Development | $3,134,935 | $1,377,028 | $2,240,270 | $1,950,500 |
| Selling General And Administration | $10,275,914 | $5,897,594 | $6,491,704 | $6,694,619 |
| Other Gand A | $10,275,914 | $5,897,594 | $6,491,704 | $6,694,619 |
| Total Unusual Items | - | - | $0 | $122,520 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $122,520 |
| Other Special Charges | - | - | - | $-122,520 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-514,897 | $-2,205,843 | $-10,622 | $6,042,209 |
| Total Assets | $1,643,122 | $555,715 | $2,123,019 | $8,990,178 |
| Total Non Current Assets | $7,680 | $130,338 | $221,340 | $30,225 |
| Non Current Prepaid Assets | $7,680 | $32,058 | $32,058 | $3,000 |
| Current Assets | $1,635,442 | $425,377 | $1,901,679 | $8,959,953 |
| Prepaid Assets | $90,789 | $147,262 | $102,416 | $58,078 |
| Receivables | $2,211 | $3,735 | $0 | - |
| Accounts Receivable | $2,211 | $3,735 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $1,542,442 | $274,380 | $1,799,263 | $8,901,875 |
| Cash And Cash Equivalents | $1,542,442 | $274,380 | $1,799,263 | $8,901,875 |
| Cash Financial | $1,542,442 | $274,380 | $1,799,263 | $8,901,875 |
| Gross Accounts Receivable | - | $3,735 | $0 | - |
| Debt | ||||
| Total Debt | $254,361 | $346,342 | $445,178 | $255,178 |
| Long Term Debt And Capital Lease Obligation | $116,197 | $0 | $105,919 | $0 |
| Long Term Debt | $116,197 | - | - | - |
| Current Debt And Capital Lease Obligation | $138,164 | $346,342 | $339,259 | $255,178 |
| Current Debt | $138,164 | $240,000 | $240,000 | $240,000 |
| Other Current Borrowings | $138,164 | $240,000 | $240,000 | $240,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,158,019 | $2,761,558 | $2,133,641 | $2,947,969 |
| Total Non Current Liabilities Net Minority Interest | $116,197 | $0 | $105,919 | $0 |
| Current Liabilities | $2,041,822 | $2,761,558 | $2,027,722 | $2,947,969 |
| Payables And Accrued Expenses | $807,480 | $1,266,446 | $588,956 | $750,219 |
| Interest Payable | $65,628 | $100,686 | $98,286 | $95,886 |
| Payables | $741,852 | $1,165,760 | $490,670 | $654,333 |
| Accounts Payable | $547,090 | $993,090 | $490,670 | $654,333 |
| Current Deferred Liabilities | - | $0 | $701,331 | $1,475,357 |
| Equity | ||||
| Common Stock Equity | $-514,897 | $-2,205,843 | $-10,622 | $6,042,209 |
| Total Equity Gross Minority Interest | $-514,897 | $-2,205,843 | $-10,622 | $6,042,209 |
| Stockholders Equity | $-514,897 | $-2,205,843 | $-10,622 | $6,042,209 |
| Retained Earnings | $-136,966,550 | $-123,581,714 | $-115,804,530 | $-107,059,237 |
| Other | ||||
| Ordinary Shares Number | $3,621,335 | $2,382,356 | $1,569,943 | $1,569,943 |
| Share Issued | $3,621,335 | $2,382,356 | $1,569,943 | $1,569,943 |
| Tangible Book Value | $-514,897 | $-2,205,843 | $-10,622 | $6,042,209 |
| Invested Capital | $-260,536 | $-1,965,843 | $229,378 | $6,282,209 |
| Working Capital | $-406,380 | $-2,336,181 | $-126,043 | $6,011,984 |
| Capital Lease Obligations | $0 | $106,342 | $205,178 | $15,178 |
| Total Capitalization | $-398,700 | $-2,205,843 | $-10,622 | $6,042,209 |
| Additional Paid In Capital | $136,448,032 | $121,373,488 | $115,792,338 | $113,092,026 |
| Capital Stock | $3,621 | $2,383 | $1,570 | $9,420 |
| Common Stock | $3,621 | $2,383 | $1,570 | $9,420 |
| Current Capital Lease Obligation | $0 | $106,342 | $99,259 | $15,178 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,096,178 | $1,148,770 | $398,176 | $467,215 |
| Current Accrued Expenses | $65,628 | $100,686 | $98,286 | $95,886 |
| Dueto Related Parties Current | $194,762 | $172,670 | $0 | - |
| Net PPE | $0 | $98,280 | $189,282 | $27,225 |
| Gross PPE | $0 | $98,280 | $189,282 | $27,225 |
| Long Term Capital Lease Obligation | - | $0 | $105,919 | $0 |
| Other Properties | - | $98,280 | $189,282 | $27,225 |
| Accumulated Depreciation | - | - | - | $-100,000 |
| Machinery Furniture Equipment | - | - | - | $20,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,313,510 | $-5,799,893 | $-7,102,612 | $-6,803,333 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,313,510 | $-5,799,893 | $-7,102,612 | $-6,803,333 |
| Cash Flow From Continuing Operating Activities | $-4,313,510 | $-5,799,893 | $-7,102,612 | $-6,803,333 |
| Operating Gains Losses | - | - | - | $-122,520 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,602,269 | $640,000 | $0 | $17,209,477 |
| Financing Cash Flow | $5,581,572 | $4,275,010 | $0 | $15,567,346 |
| Cash Flow From Continuing Financing Activities | $5,581,572 | $4,275,010 | $0 | $15,567,346 |
| Net Common Stock Issuance | $5,602,269 | $640,000 | $0 | $17,209,477 |
| Common Stock Issuance | $5,602,269 | $640,000 | $0 | $17,209,477 |
| Net Other Financing Charges | - | - | - | $-1,697,828 |
| Other | ||||
| Repayment Of Debt | $-538,257 | $-1,755,600 | $-628,600 | $-190,500 |
| Issuance Of Debt | $517,560 | $1,755,600 | $628,600 | $190,500 |
| Interest Paid Supplemental Data | $18,955 | $72,178 | $10,920 | $3,084 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $1,542,442 | $274,380 | $1,799,263 | $8,901,875 |
| Beginning Cash Position | $274,380 | $1,799,263 | $8,901,875 | $137,862 |
| Changes In Cash | $1,268,062 | $-1,524,883 | $-7,102,612 | $8,764,013 |
| Proceeds From Stock Option Exercised | $0 | $3,635,010 | $0 | $55,697 |
| Net Issuance Payments Of Debt | $-20,697 | $0 | $0 | $0 |
| Net Long Term Debt Issuance | $-20,697 | $0 | $0 | $0 |
| Long Term Debt Payments | $-538,257 | $-1,755,600 | $-628,600 | $-190,500 |
| Long Term Debt Issuance | $517,560 | $1,755,600 | $628,600 | $190,500 |
| Change In Working Capital | $-500,467 | $1,280,668 | $-355,393 | $-394,127 |
| Change In Other Current Liabilities | $-106,342 | $-98,835 | $-51,695 | $-29,171 |
| Change In Payables And Accrued Expense | $-476,500 | $1,428,084 | $-230,302 | $-422,135 |
| Change In Accrued Expense | $-52,592 | $752,994 | $-66,639 | $483,160 |
| Change In Payable | $-423,908 | $675,090 | $-163,663 | $-905,295 |
| Change In Account Payable | $-423,908 | $675,090 | $-163,663 | $-905,295 |
| Change In Prepaid Assets | $80,851 | $-44,846 | $-73,396 | $-28,125 |
| Change In Receivables | $1,524 | $-3,735 | $0 | - |
| Changes In Account Receivables | $1,524 | $-3,735 | $0 | - |
| Other Non Cash Items | $98,280 | $-170,736 | $-694,388 | $-500,832 |
| Stock Based Compensation | $9,473,513 | $867,359 | $2,692,462 | $2,970,027 |
| Net Income From Continuing Operations | $-13,384,836 | $-7,777,184 | $-8,745,293 | $-8,755,881 |
| Net Short Term Debt Issuance | - | $0 | $0 | - |
| Short Term Debt Payments | - | $-1,755,600 | $-628,600 | - |
| Short Term Debt Issuance | - | $1,755,600 | $628,600 | - |
| Change In Other Working Capital | - | - | - | $85,304 |
| Gain Loss On Investment Securities | - | - | - | $32,775 |
Fetched: 2026-02-02